NASDAQ:MNKD MannKind (MNKD) Stock Price, News & Analysis → Elon Musk Secret Crypto Plot Exposed (From Crypto 101 Media) (Ad) Free MNKD Stock Alerts $4.32 +0.01 (+0.23%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$4.23▼$4.4550-Day Range$4.05▼$5.2752-Week Range$3.17▼$5.75Volume1.90 million shsAverage Volume1.88 million shsMarket Capitalization$1.18 billionP/E Ratio144.05Dividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get MannKind alerts: Email Address MannKind MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside85.2% Upside$8.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 19 Articles This WeekInsider TradingN/AProj. Earnings Growth60.00%From $0.10 to $0.16 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.70 out of 5 starsMedical Sector436th out of 921 stocksPharmaceutical Preparations Industry196th out of 428 stocks 3.5 Analyst's Opinion Consensus RatingMannKind has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMannKind has only been the subject of 2 research reports in the past 90 days.Read more about MannKind's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for MNKD. Previous Next 0.0 Dividend Strength Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNKD. Previous Next 2.6 News and Social Media Coverage News SentimentMannKind has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for MannKind this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of MannKind is held by insiders.Percentage Held by Institutions49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MannKind's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for MannKind are expected to grow by 60.00% in the coming year, from $0.10 to $0.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is -86.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is -86.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about MannKind's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About MannKind Stock (NASDAQ:MNKD)MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Read More MNKD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNKD Stock News HeadlinesMay 11, 2024 | americanbankingnews.comLeerink Partnrs Analysts Lower Earnings Estimates for MannKind Co. (NASDAQ:MNKD)May 10, 2024 | markets.businessinsider.comMannKind Buy Rating Affirmed by Analyst Thomas Smith on Strong Revenue Growth and Promising Clinical DevelopmentsMay 11, 2024 | Banyan Hill Publishing (Ad)CEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.May 10, 2024 | finance.yahoo.comMannKind First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | finance.yahoo.comMannKind Corp (MNKD) Q1 2024 Earnings Call Transcript Highlights: A Quarter of Robust Growth ...May 9, 2024 | finance.yahoo.comMannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comShareholders May Not Be So Generous With MannKind Corporation's (NASDAQ:MNKD) CEO Compensation And Here's WhyMay 8, 2024 | msn.comMNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024May 11, 2024 | Banyan Hill Publishing (Ad)CEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.May 8, 2024 | markets.businessinsider.comMannKind Corp. Q1 Earnings SummaryMay 8, 2024 | globenewswire.comMannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development UpdateMay 6, 2024 | finance.yahoo.comMannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseMay 6, 2024 | globenewswire.comMannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseMay 1, 2024 | globenewswire.comMannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024April 30, 2024 | globenewswire.comMannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesApril 29, 2024 | marketwatch.comMannKind Gets FDA Clearance for Clofazimine IND ApplicationApril 29, 2024 | markets.businessinsider.comMannKind Gets FDA Nod For Phase 3 Study Of Clofazimine Inhalation Suspension For NTM Lung DiseaseApril 29, 2024 | msn.comMannKind rises as FDA advances rare lung disease therapy to Phase 3 trialApril 29, 2024 | globenewswire.comMannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseApril 3, 2024 | globenewswire.comMannKind Repays Certain Debt ObligationsApril 1, 2024 | finance.yahoo.comMannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returnsMarch 30, 2024 | nasdaq.comMay 10th Options Now Available For MannKind (MNKD)March 28, 2024 | uk.investing.comMannKind CFO Steven Binder to retire, Chris Prentiss to take overMarch 26, 2024 | globenewswire.comMannKind Announces CFO TransitionMarch 25, 2024 | finance.yahoo.comJim Cramer Says You Should Avoid These 11 StocksMarch 17, 2024 | finance.yahoo.comMNKD Mar 2024 5.000 putMarch 16, 2024 | finance.yahoo.comMNKD Mar 2024 4.000 callSee More Headlines Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/10/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MNKD CUSIP56400P20 CIK899460 Webwww.mannkindcorp.com Phone(818) 661-5000Fax661-775-2081Employees411Year Founded1991Price Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.50 Potential Upside/Downside+85.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E Ratio43.20 P/E GrowthN/ANet Income$-11,940,000.00 Net Margins-6.00% Pretax Margin-5.22% Return on EquityN/A Return on Assets-3.62% Debt Debt-to-Equity RatioN/A Current Ratio3.59 Quick Ratio3.31 Sales & Book Value Annual Sales$198.96 million Price / Sales5.88 Cash FlowN/A Price / Cash FlowN/A Book Value($0.91) per share Price / Book-4.75Miscellaneous Outstanding Shares270,679,000Free Float262,559,000Market Cap$1.17 billion OptionableOptionable Beta1.34 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Michael E. Castagna Pharm.D. (Age 47)CEO & Director Comp: $1.53MMs. Lauren M. Sabella (Age 63)Executive VP & COO Comp: $1.39MDr. David B. Thomson J.D. (Age 57)Ph.D., Executive VP, General Counsel & Secretary Comp: $862.23kDr. Stuart A. Tross Ph.D. (Age 57)Executive VP and Chief People & Workplace Officer Comp: $739.45kMr. Steven B. Binder (Age 61)Executive Vice President of Special Projects Comp: $854.28kMr. Christopher B. Prentiss M.B.A. (Age 49)Chief Financial Officer Mr. Sanjay Singh M.B.A. (Age 58)Executive Vice President of Technical Operations Comp: $364.53kMs. Rosabel Realica Alinaya (Age 63)VP of Investor Relations & Treasury Comp: $402.26kMr. John F. Bedard (Age 74)Senior Vice President of Worldwide Regulatory Affairs Mr. James Patrick McCauley Jr. (Age 58)J.D., M.B.A., Chief Commercial Officer Comp: $614.06kMore ExecutivesKey CompetitorsIronwood PharmaceuticalsNASDAQ:IRWDLigand PharmaceuticalsNASDAQ:LGNDInnovivaNASDAQ:INVAOPKO HealthNASDAQ:OPKDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 107,899 shares on 5/10/2024Ownership: 5.594%State Board of Administration of Florida Retirement SystemSold 4,820 shares on 5/9/2024Ownership: 0.025%ProShare Advisors LLCBought 5,416 shares on 5/8/2024Ownership: 0.024%Susquehanna Fundamental Investments LLCBought 99,267 shares on 5/7/2024Ownership: 0.037%SG Americas Securities LLCSold 150,629 shares on 5/7/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions MNKD Stock Analysis - Frequently Asked Questions Should I buy or sell MannKind stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MNKD shares. View MNKD analyst ratings or view top-rated stocks. What is MannKind's stock price target for 2024? 3 equities research analysts have issued 1-year target prices for MannKind's shares. Their MNKD share price targets range from $6.50 to $10.00. On average, they predict the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 85.2% from the stock's current price. View analysts price targets for MNKD or view top-rated stocks among Wall Street analysts. How have MNKD shares performed in 2024? MannKind's stock was trading at $3.64 at the beginning of the year. Since then, MNKD stock has increased by 18.7% and is now trading at $4.32. View the best growth stocks for 2024 here. When is MannKind's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our MNKD earnings forecast. How were MannKind's earnings last quarter? MannKind Co. (NASDAQ:MNKD) released its earnings results on Wednesday, May, 8th. The biopharmaceutical company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.02. The biopharmaceutical company earned $66.26 million during the quarter, compared to the consensus estimate of $60.55 million. The firm's quarterly revenue was up 63.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.04) earnings per share. What ETFs hold MannKind's stock? ETFs with the largest weight of MannKind (NASDAQ:MNKD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD). Who are MannKind's major shareholders? MannKind's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.59%), 180 Wealth Advisors LLC (0.72%), TSP Capital Management Group LLC (0.30%), GSA Capital Partners LLP (0.23%), Simplex Trading LLC (0.00%) and Hennion & Walsh Asset Management Inc. (0.09%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross. View institutional ownership trends. How do I buy shares of MannKind? Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MNKD) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
